Avisi Technologies’ investigational device exemption (IDE) submission for its glaucoma treatment device VisiPlate has been approved by the US Food and Drug Administration (FDA).
Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback